Paclitaxel and Cisplatin in Advanced or Recurrent Carcinoma of the Endometrium: Long-Term Results of a Phase II Multicenter Study

摘要: Abstract Objectives. Both paclitaxel and cisplatin have moderate activity in patients with metastatic or recurrent carcinoma of the endometrium, combination these two agents has shown a variety solid tumors. We administered this to endometrium evaluate its define toxicity. Methods. Twenty-four consecutive were treated on an outpatient basis 175 mg/m 2 intravenously over 3-h period followed by 75 granulocyte colony-stimulating factor (G-CSF) support. The chemotherapy was repeated every 3 weeks for maximum six courses. Results. Sixteen (67%; 95% confidence interval, 45–84%) achieved objective response, including seven complete responses nine partial responses. median duration response 7 months, times progression survival all 8.4 17.6 respectively. Some degree neurotoxicity occurred 44% patients. Grade 4 toxicity included granulocytopenia 22% peripheral neuropathy 9%. Conclusion. G-CSF support appears active endometrium. significant incidence is concern alternative methods administration could be evaluated.